# Biotricity Revenue Climbs 11.5% as Operating Income Rises 23.7%

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/62088
Published: 2026-11-20T13:48:48.000Z
Updated: 2026-11-20T13:48:48.000Z
Section: Business

> Gross margin reached 83.3%, while net loss attributable to common stockholders widened to $950,000.

Biotricity Inc. reported $4.33 million in revenue for fiscal 2027’s second quarter, an 11.5% year-over-year increase, while operating income rose 23.7% as gross profit growth outpaced higher expenses. The medical technology company provides remote cardiac monitoring solutions.

The quarter ended Sept. 30, 2026, and Biotricity announced the results Nov. 20. Technology fee revenue increased 13.3% to $3.98 million, accounting for 91.8% of total revenue, compared with 90.4% in the year-earlier quarter.

Gross margin rose to 83.3% from 81.9%, and gross profit increased 13.4% to $3.61 million. Income from operations grew 23.7% to $339,000, equal to a 7.8% operating margin, up from 7% a year earlier.

Operating expenses increased 12.5% to $3.27 million. Research and development expenses rose 46.7% to $880,000.

Net loss before dividends totaled $810,000, compared with $690,000 a year earlier. The latest quarter included a $151,000 noncash loss tied to a change in the fair value of derivative liabilities. Net loss attributable to common stockholders was $950,000, or 4.6 cents per share, versus $770,000, or 2.9 cents per share, a year earlier.

For the six months ended Sept. 30, 2026, revenue increased 11% to $8.61 million. Net cash provided by operating activities was $511,000, compared with $42,000 in the prior-year period.

Biotricity began an 18-month pilot in October under a national distribution agreement that is subject to a successful pilot. If the pilot succeeds, the agreement provides for the partner to fund commercial expansion in exchange for a 30% distribution margin.

In October, the company was selected to provide cardiac screenings for patients in low-income communities and developing countries through a charitable program. Biotricity expects at least 1,000 devices to be deployed, but the timing and scale of deployment and the revenue ultimately recognized are uncertain.


